首页> 外国专利> Meningococcal conjugate vaccine for groups A, C, Y and W135 and a preparation method thereof

Meningococcal conjugate vaccine for groups A, C, Y and W135 and a preparation method thereof

机译:A,C,Y和W135群的脑膜炎球菌结合疫苗及其制备方法

摘要

The present invention provides a meningococcal conjugate vaccine for groups A, C, Y and W135, which is a tetravalent conjugate vaccine comprising polysaccharide-protein conjugates obtained by respectively conjugating a capsular polysaccharide of Neisseria meningitides groups A, C, Y and W135 to a outer membrane vesicle protein selected from a group consisting of Neisseria meningitides group B serotypes 4 and 15 outer membrane vesicle proteins. The meningococcal conjugate vaccine provided by the present invention may effectively avoid the risk of affecting the immune response to vaccines resulting from immune tolerance and competition between antigenic sites existing in multivalent conjugate vaccines prepared from a single carrier protein; the meningococcal conjugate vaccine provided by the present invention may avoid the safety risk of allergic reactions, toxicity reversion and the like which exist in conjugate vaccines prepared by using TT and DT as carrier proteins; and the meningococcal conjugate vaccine provided by the present invention may enhance immunity to Neisseria meningitides group A and provide a bactericidal antibody having relatively extensive protective effect against Neisseria meningitides group B. Meanwhile, the present invention provides a complete production process of a meningococcal conjugate vaccine for groups A, C, Y and W135, which is applicable to large-scale production. Studies have demonstrated that the present vaccine has good immunogenicity, reliable safety and stable immunity persistence.
机译:本发明提供了用于A,C,Y和W135组的脑膜炎球菌结合疫苗,其是包含分别通过将脑膜炎奈瑟氏球菌A,C,Y和W135组的荚膜多糖结合到外部而获得的多糖-蛋白结合物的四价结合疫苗。膜囊泡蛋白选自脑膜炎奈瑟氏球菌B组血清型4和15的外部膜囊泡蛋白。本发明提供的脑膜炎球菌结合疫苗可有效避免影响由单一载体蛋白制备的多价结合疫苗中存在的抗原结合位点之间的免疫耐受和竞争而导致的对疫苗免疫反应的风险。本发明提供的脑膜炎球菌结合疫苗可以避免以TT和DT为载体蛋白制备的结合疫苗存在的变态反应,毒性逆转等安全风险。本发明提供的脑膜炎球菌结合疫苗可以增强对脑膜炎奈瑟菌群A的免疫力,提供对脑膜炎奈瑟菌群B具有相对广泛的保护作用的杀菌抗体。同时,本发明提供了一种完整的脑膜炎球菌结合疫苗的生产方法。组A,C,Y和W135,适用于大规模生产。研究表明,本疫苗具有良好的免疫原性,可靠的安全性和稳定的免疫持久性。

著录项

  • 公开/公告号US10046042B2

    专利类型

  • 公开/公告日2018-08-14

    原文格式PDF

  • 申请/专利权人 BEIJING SANROAD BIOLOGICAL PRODUCTS CO. LTD.;

    申请/专利号US201615197369

  • 发明设计人 WANG JIANHUA;

    申请日2016-06-29

  • 分类号A61K39/095;A61K39;A61K39/116;C07K14/22;

  • 国家 US

  • 入库时间 2022-08-21 13:05:47

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号